Goleta, Calif., July 3, 2012 – Vascular BioSciences announced today that Dr. Kalju Kahn, PhD, has been named head of Medicinal Chemistry.
Dr. Kahn, an expert in computational chemistry and drug design at the University of California Santa Barbara, brings a wealth of expertise and a passion for chemistry to our drug development efforts. “We are very excited about the addition of Dr. Kahn as head of medicinal chemistry to our team,” remarked CEO David Mann, “Kalju brings a wealth of technical excellence and a deep understanding of the underlying chemistry that is of great value as we explore the correlation between molecular structure and pharmacological activity of our targeted therapeutic compounds.”
Dr. Kahn commented, “I look forward to contributing my talents in computational chemistry and drug design to help advance the exciting new therapeutic agents we are developing at VBS. I believe that with my broad background in experimental biochemistry and expertise in computational analysis of biomolecular interactions, I can significantly contribute toward achieving our goal to develop novel solutions for hard to treat diseases.”
About Vascular BioSciences
Vascular BioSciences, a diversified biomedical company with operations in California and North Carolina, provides disease solutions in order to enhance and prolong human life.
Vascular BioSciences makes interventional catheters to obtain endoarterial biopsies, provides molecular diagnostic services, and through its majority owned subsidiary VBS Pharmaceuticals, develops targeted therapeutics for patients with difficult‒to‒treat diseases.